Newsbenzinga
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
· Published
Article summary
aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.
An excerpt from the original article.
Comments —
Loading comments…